化学合成两类去唾液酸糖蛋白受体(ASGPR)的人工配体——半乳糖基白蛋白(GalnHSA)和半乳糖基多聚-L-谷氨酸(GalnPLGA), 并以 125I标记的去唾液酸胎球蛋白(ASF)为标准配体,测定了合成配体抑制 125I-ASF与大鼠肝细胞膜ASGPR结合的IC50值. 结果表明,Gal12HSA、Gal15HSA、Gal26HSA、Gal30HSA和Gal34PLGA均能够有效地抑制 125I-ASF与ASGPR的结合,且前者与ASGPR的亲和力随半乳糖基化程度的增加而增加. 这些合成配体来源丰富、制备简单,适合于作为药物或基因肝靶向运送的导向配体.
Two kinds of artificial ligand of asialoglycoprotein receptor (ASGPR), galactosyl human serum albumin (GalnHSA) and galactosyl poly-L-glutamic acid (GalnPLGA), were synthesized chemically. IC50 of synthetic ligands inhibiting the binding of 125I-asialofetuin (125I-ASF) to ASGPR of rat liver cell membrane were assayed. The results showed that Gal12HSA, Gal15HSA, Gal26HSA, Gal30HSA and Gal34-PLGA could all efficiently inhibit the binding of 125I-ASF to ASGPR. The affinities of GalnHSA increased along with the increase of the coupling number of galactosyl. Here, the synthesis and the affinity identification of Gal34PLGA with ASGPR were firstly reported. These synthetic ligands with abundant sources and simple preparations may be used as targeting ligands for the liver-targeting delivery of drugs or genes.
李崇辉,温守明,池木根,孙曼霁.肝靶向配体半乳糖基白蛋白和多聚谷氨酸[J].生物化学与生物物理进展,1998,25(6):532-535
复制生物化学与生物物理进展 ® 2025 版权所有 ICP:京ICP备05023138号-1 京公网安备 11010502031771号